Safety of bioabsorbable polymer against durable polymer DES in high-risk PCI patients

May 14, 2020

WASHINGTON - A novel study sought to reveal whether drug-eluting stents (DES) coated with bioabsorbable polymer (BP) presented a safety advantage without compromising efficacy compared to durable polymer (DP) formulations. Subgroup findings from the TWILIGHT trial were presented today during the SCAI 2020 Scientific Sessions Virtual Conference.

The study examined the SYNERGY platform in a higher risk patient population than previously studied. In addition, the investigators evaluated the effect ticagrelor monotherapy in such patients, which has not been done in previous studies. Ticagrelor is a blood thinner that has been found to prevent stroke, heart attack, and other heart problems.

Investigators conducted a pre-specified analysis among patients enrolled in the TWILIGHT trial treated with the BP everolimus-eluting stent (BP-EES) or a DP-DES. Following successful percutaneous coronary intervention (PCI) and 3 months of ticagrelor plus aspirin, patients were randomized to aspirin or placebo for 1 year; DES choice was at physician discretion. The primary endpoint was target lesion failure (TLF) [composite of cardiac death, target vessel myocardial infarction (MI), clinically driven target lesion revascularization (TLR) or definite/probable stent thrombosis (ST)].

Patients receiving BP-EES (n = 653; 9.2%) were more frequently randomized in North America and had a lower frequency of prior MI compared to those receiving DP-DES (n = 6404; 90.8%); total stent length was approximately 39 mm in both groups. One-year rates of TLF were 6.4% and 6.1% in the BP-EES and DP-DES groups, respectively (p = 0.72). Analogous rates of def/prob ST and TLR were 0.8% vs 0.9% (p = 0.49) and 5.3% vs 4.4% (p = 0.96). The effect of ticagrelor monotherapy on ischemic and bleeding events was uniform across DES groups (all pint >0.10).

"Our work shows that the SYNERGY stent performs similarly to other durable polymer DES in relatively high-risk patients enrolled in the TWILIGHT trial," said Usman Baber, MD, lead author of the study. "This is a clinically relevant finding as it provides randomized evidence supporting the use of this platform in such patients. In addition, the effect of ticagrelor monotherapy on ischemic and bleeding events observed in the overall trial was preserved among patients receiving a SYNERGY DES, suggesting this strategy may be a safe alternative in high bleeding risk patients treated with the SYNERGY stent."

"These findings broaden the generalizability of adopting a strategy of P2Y12 inhibitor monotherapy to patients treated with different DES platforms," continued Baber. "In addition, our results provide reassurance that the SYNERGY platform performs similarly to other newer-generation DES in high-risk patients."

Abstract #11754 "Safety and efficacy of the biodegradable-polymer everolimus-eluting stent versus durable-polymer drug-eluting stents in high-risk patients undergoing PCI: Insights from the TWILIGHT trial." SCAI 2020 Scientific Sessions Virtual Conference, May 14-16, 2020.
-end-
About the Society for Cardiovascular Angiography and Interventions

The Society for Cardiovascular Angiography and Interventions (SCAI) is a professional member organization representing 5,000 invasive and interventional cardiologists in approximately 75 nations. SCAI's mission is to promote excellence invasive and interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care. For more information about SCAI, visit http://www.scai.org and http://www.secondscount.org. Follow @SCAI on Twitter for the latest heart health news.

Society for Cardiovascular Angiography and Interventions

Related Ticagrelor Articles from Brightsurf:

Clinical trial shows potential benefit to anti-platelet therapy
Heart patients who undergo percutaneous coronary intervention (PCI) or stent placement? nonsurgical procedures to improve blood flow to the heart are typically prescribed anti-platelet therapy to avoid blood clots that can lead to a heart attack or stroke.

Cardiology trial shows potential benefit of genetic testing when selecting blood thinners
An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce by 34 per cent the number of serious adverse events following balloon angioplasty, a treatment for the most common form of heart disease.

Safety of bioabsorbable polymer against durable polymer DES in high-risk PCI patients
A novel study sought to reveal whether drug-eluting stents (DES) coated with bioabsorbable polymer (BP) presented a safety advantage without compromising efficacy compared to durable polymer (DP) formulations.

Precision medicine guides choice of better drug therapy in severe heart disease
Is personalized medicine cost-effective? Researchers have answered that question for one medical treatment, genotype-guided antiplatelet therapy for acute coronary syndrome patients with PCI.

Benefit seen for ticagrelor alone, without aspirin, in patients with ACS
The research was presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Ticagrelor alone, without aspirin, shows benefit in patients with diabetes
Patients with diabetes who stopped taking aspirin three months after the insertion of a coronary stent and then took the anti-platelet medication ticagrelor alone for a year had fewer episodes of bleeding and no increase in heart attacks, stroke or other adverse events caused by blockages in the arteries, compared with patients who took both aspirin and ticagrelor for a year.

Dropping aspirin for ticagrelor alone better in complex heart disease
The research, a subanalysis of the TWILIGHT trial, was presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Genetic testing for antiplatelet therapy post-PCI misses cut in cardiovascular events
An international clinical trial that used genetic testing to guide which antiplatelet medication was given to patients following percutaneous coronary intervention (PCI) did not meet its stated goal for cutting in half the incidence of serious adverse cardiovascular events, such as heart attack and stroke, in the year following the procedure, according to study results presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Additional heart artery stenting reduces risk of future heart attacks
Research has shown that patients who have had emergency heart attack treatment with heart artery stenting -- and have significant narrowings in their other untreated arteries -- can benefit from additional stenting to help prevent future heart attacks.

The Lancet journals: Papers at ESC Congress 2019
The following papers will be presented at the ESC Congress 2019, organised by the European Society of Cardiology in Paris and published simultaneously in either The Lancet or The Lancet Global Health journals.

Read More: Ticagrelor News and Ticagrelor Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.